Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...
This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet...
TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| Symbole | Prix | Vol. |
|---|---|---|
| LITMSnow Lake Resources Ltd | US$ 0,6857 (274,70%) | 532,66M |
| CGTXCognition Therapeutics Inc | US$ 0,874808 (92,31%) | 211,52M |
| TNXPTonix Pharmaceuticals Holding Corporation | US$ 0,393 (17,70%) | 193,03M |
| RGTIRigetti Computing Inc | US$ 10,98 (-1,35%) | 143,83M |
| CEROCERo Therapeutics Holdings Inc | US$ 0,069 (12,93%) | 121,1M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
